CME-Directory

The Expert Perspectives: Integrating New Data Into Best Practices for Breast Cancer satellite symposium focuses on 3 controversial aspects of breast cancer therapy, highlighting recent advances in molecular assay–based risk assessment for node-negative and node-positive disease, therapeutic approaches to early-stage and advanced triple-negative breast cancer, and optimal strategies for the management of patients with early-stage or metastatic HER2+ breast cancer. Leading experts in the field of breast cancer will present cases illustrating areas of debate followed by their perspectives on the interpretation and application of recent clinical data and guidelines in order to increase the ability of participants to apply new data to their clinical practice and improve patient care. Not an official event of the ASCO Breast Cancer Symposium. Not sponsored or endorsed by any of the co-sponsoring organizations of the ASCO Breast Cancer Symposium.

This activity is presented by Physicians’ Education Resource in conjunction with the University of California, Davis Cancer Center and the support of community oncologists from diverse practices within Northern California (Kaiser Permanente, Sacramento Center for Hematology and Medical Oncology, Capitol Hematology Oncology, and Sierra Hematology Oncology). For the past nine years, the annual Advances in Oncology symposium has provided a unique educational opportunity for physicians in the Greater Sacramento and Northern California area. The 10th Annual Advances in Oncology program will once again bring together academic and community physicians for the purpose of educating participants on the state-of-the-art clinical management of a wide variety of solid and hematologic malignancies. Furthermore, the timing of this meeting in September allows for the latest findings in clinical cancer research from major international oncology conferences to be presented. This symposium has been designed to update physicians on recent advances and new diagnostic and treatment modalities in the management of hematologic, colorectal, lung, genitourinary, and breast cancers. This symposium also meets a unique need for the Northern Sacramento Valley to provide a group of networked and collaborating oncologists to exchange and apply recent developments in oncology in the context of local treatment approaches, patient populations, referral patterns, and open clinical trials. This is reflected in the format providing ample time for panel discussions that involve a large array of local practicing oncologists. The program will include didactic sessions from leading faculty followed by extensive interactive case-based panel discussions involving community-based physicians to discuss solutions to clinical challenges that physicians face in their daily practice. The knowledge transmitted through this program, together with partnerships with UC Davis physicians, will improve cancer care for patients in the Northern California region. Additional CME Accreditation and Credit Designation Information Registered Nurse: The California Board of Registered Nursing accepts AMA PRA Category 1 CreditsTM toward license renewal. On the BRN license renewal form, report the number of hours you attended (up to XX hours of credit) and fill in “CME Category 1” for the provider number. California AB 1195: This activity complies with California Assembly Bill 1195, signed November 2005, requiring continuing medical education courses with patient care components to include curricula in the subject of cultural and linguistic competency. The planners, speakers and authors of this CME activity have been encouraged to address issues relevant in their topic area. Target Audience This educational program is directed toward medical, radiation, and surgical oncologists with an interest in recent advances in the treatment of solid tumors as well as hematologic malignancies. Fellows, oncology nurses, oncology physician assistants, and pharmacists are also invited to attend. Learning Objectives At the conclusion of this symposium you should be able to: Discuss prognostic and predictive biomarkers and potential applications in therapeutic decision making Integrate targeted and traditional therapeutic modalities in the treatment of cancer Assess newly validated treatment options for patients with solid tumors or hematologic malignancies Apply data from clinical trials to determine the optimal course of therapy in defined patient populations

The purpose of the 10th International Lung Cancer Congress is to update participants on advances in lung cancer, including biology, pathology, staging, individualized therapy, novel agents, and supportive care. The congress will discuss current trends in surgical, radiotherapeutic, and chemotherapeutic approaches to lung cancer and will provide a perspective on clinical data presented at major international oncology meetings. An ongoing focus will be the individualization of therapy based on clinical, histologic, and molecular characteristics. Areas of controversy in lung cancer therapy, including treatment of early-stage and locally advanced disease, testing for molecular markers, and the optimal combination of targeted and cytotoxic agents will be the subject of panel discussions and debates. The congress will also feature presentations on optimizing the application of established targeted agents as well as presentations introducing emerging targeted agents, including mechanisms of action and clinical/preclinical results. A regular feature of the International Lung Cancer Congress is an update of research efforts from major Cooperative Groups in the United States, Europe, and Asia. The format of the meeting will include didactic lectures from internationally renowned leaders, debates and discussions on controversial topics, extensive panel discussions with case scenarios, multidisciplinary tumor boards, and question-and-answer sessions as well as afternoon translational workshops focusing on strategies currently in development for the treatment of lung cancer. This educational program is directed toward medical oncologists, radiation oncologists, thoracic surgeons, and pulmonologists as well as investigators, practitioners, and fellows in training with research interests in lung cancer. No specific skills or knowledge other than a basic training in oncology is required for successful participation in this activity. Nurses, physician assistants, and other individuals interested in the treatment of lung cancer are also invited to attend.

The purpose of the 11th International Lung Cancer Congress is to provide participants with an update on advances in the field of lung cancer, including biology, pathology, staging, personalized therapy, maintenance therapy, novel agents, and ongoing research in Cooperative Groups. Bringing key data from international oncology conferences to participants, the congress will emphasize the importance of personalized therapy and address other current topics of interest, such as maintenance therapy and novel targeted agents. State-of-the-art treatment for early-stage locally advanced and metastatic lung cancer will be discussed. In addition to non–small-cell lung cancer (NSCLC), the congress will address therapy for small-cell lung cancer (SCLC) and mesothelioma. A regular feature of the International Lung Cancer Congress is an update of research efforts from major Cooperative Groups from the United States, Europe, and Asia. The format of the meeting will include didactic lectures from internationally renowned leaders, debates and discussions on controversial topics, extensive panel discussions with case scenarios, multidisciplinary tumor boards, question-and-answer sessions, and afternoon translational workshops focusing on future strategies in development for the treatment of lung cancer

Held in Conjunction With the 10th Annual Medical Oncology Fellows Forum Important advances in the field of oncology over the last several years have led to improvements in outcome for several malignancies and newer options for refractory disease. This has resulted in a need to improve performance in clinical practice through the understanding of how to optimally individualize care based on benefits and risks in specific situations and defined patient populations. The 13th Annual Fall Oncology Conference: Clinical Challenges in Cancer Medicine has been designed to address clinical challenges and practical issues faced each day by community oncologists, oncology nurses, oncology physician’s assistants and other oncology professionals. The conference is intended to inform oncology professionals and fellows in training of the recent data on agents approved for and being evaluated in the most common tumor types, including breast, lung, genitourinary, gastrointestinal, gynecological and hematologic malignancies, and sarcoma. In addition, this activity focuses on providing a thorough understanding of the toxicity profiles of controversial and evolving regimens with hormonal therapy, chemotherapy, and novel targeted agents so as to aid oncology professionals in making effective decisions regarding treatment, management of patients and trial enrollment.

Over the past decade, an increasing number of oncologists have concentrated their practices on breast cancer. In order to advance patient care, the School of Breast Oncology was developed. This curriculum-based program focuses exclusively on breast cancer clinical management. The intensive 4-day interactive program will provide a comprehensive review of data on the most important aspects of breast cancer biology, diagnostics, prevention, and treatment. The curriculum will be evidence based, summarizing the existing data for each topic and applying these data to patient cases.

During this three and a half day conference, you will benefit from an intimate learning environment where renowned faculty will present the latest in oncology care. In addition to the rich educational program, you will appreciate the venue’s comfort and exceptional service, along with a well organized format allowing for ample free time to enjoy San Diego’s many charms.

This course is designed for oncology nurse practitioners and clinical nurse specialists, as well as other advanced practice professionals interested in innovative oncology care. The purpose is to update the health care professional on clinical issues and current trends in cancer practice.

Chair: Jean Klastersky, MD

Chairs: Mario Dicato, MD and Eric van Cutsem, MD Abstract Deadline: 24 February 2006

The Annual Community Oncology Research Forum brings together academic and community physicians as well as oncology nurses and physician assistants in order to update participants on the state-of-the-art clinical management of a wide variety of solid and hematologic malignancies. Lectures will highlight current standards, cutting-edge information, and emerging treatment strategies for specific tumor types, followed by new clinical trial designs and patient case-based panel discussions on practical disease management. Other sessions will focus on key biologic mechanisms in cancer development as well as the ethics of clinical trials and biomedical statistics as they pertain to clinical trial design and interpretation. This meeting presents an opportunity for continuous dialogue and interaction between academic thought leaders and community oncologists.

The Current Trends in Lung Cancer and Head & Neck Cancer series of regional meetings is designed to update practicing oncologists and thoracic surgeons on recent advances in the management of lung and head & neck cancers. Attendees will be updated on long-term data on adjuvant chemotherapy in early-stage disease; in the metastatic setting, the maintenance approach to therapy will be discussed. Advances in multimodality treatment strategies for stage III NSCLC, including the integration of targeted agents, will be addressed. Updates on efforts to customize lung cancer therapy based on pharmacogenomic patient characteristics will be provided. This symposium will cover in detail current data on the use of agents that block the activity of the EGFR and VEGF pathways to treat NSCLC as well as novel therapies in development for lung cancer. Current approaches to the treatment of patients with SCLC, including novel cytotoxic and targeted agents, will also be presented. This lecture series will also review recent clinical trials in head and neck cancer investigating induction chemotherapy for locally advanced disease. Studies exploring the integration of targeted agents, including EGFR and angiogenesis inhibitors, into the treatment of head and neck cancer will be presented. These meetings will provide extensive opportunity to interact with the faculty, including ample time for questions as well as extensive case-based discussion sessions. This educational program is directed toward medical oncologists, radiation oncologists, and thoracic surgeons specializing in lung and/or head and neck cancer. Nurses, physician assistants, fellows, and pharmacists in oncology who are interested in the treatment of lung and head and neck cancers are also invited to attend.

The Duke Debates: Controversies in the Management of Patients With Hematologic Malignancies symposium is intended to update physicians, advanced practice nurses, pharmacists, physician assistants, and other health care providers on advances in lymphoma, leukemia, multiple myeloma, myelodysplastic syndromes, and supportive care. Through didactic presentations, pro/con debates, and case studies, the audience will participate in discussions concerning the diagnosis and management of a variety of hematologic malignancies. In addition to the main session, small-group breakout sessions will address advanced practice nursing, pharmacy, and hematopathology. This educational program is directed toward medical oncologists, hematologists, nurses, nurse practitioners, physician assistants, and pharmacists interested in the treatment of hematologic malignancies. Other health care professionals who are interested in the treatment of hematologic malignancies are also invited to attend.

Presented by Physicians’ Education Resource in Conjunction With Duke University School of Medicine The Duke Debates: Controversies in the Management of Patients With Hematologic Malignancies symposium is intended to update physicians, advanced practice nurses, pharmacists, physician assistants, and other health care providers on advances in lymphoma, leukemia, multiple myeloma, myelodysplastic syndromes, and supportive care. Through didactic presentations, pro/con debates, and case studies, the audience will participate in discussions concerning the diagnosis and management of a variety of hematologic malignancies. In addition to the main session, small-group breakout sessions will address advanced practice nursing, pharmacy, and hematopathology. This educational program is directed toward medical oncologists, hematologists, nurses, nurse practitioners, physician assistants, and pharmacists interested in the treatment of hematologic malignancies. Other health care professionals who are interested in the treatment of hematologic malignancies are also invited to attend.

Oncology CME-Certified Congress The Eighth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy congress will address emerging data that underlie the optimal management of early-stage breast cancer. A significant emphasis on case discussion and available adjuvant and neoadjuvant treatment options will provide a forum to discuss and debate the controversies concerning and practical applicability of evolving clinical trial findings. Other topics pertaining to diagnosis, staging, breast cancer subtypes, risk assessment, toxicity management, and survivorship issues will also be addressed. The purpose of this congress is to provide an update on the latest advances in the management of early-stage breast cancer, addressing key areas of controversy. Target Audience This educational program is directed toward medical, surgical, and radiation oncologists practicing in the community or at academic institutions. Fellows, nurses, physician assistants, and pharmacists with an interest in the treatment of breast cancer are also invited to attend. Learning Objectives At the conclusion of this congress, you should be able to: Review new diagnostic and management insights into hereditary breast cancers Describe the principles of state-of-the-art imaging and surgical techniques as well as radiation therapy and apply them to the treatment of patients with breast cancer Review the latest data on preoperative therapies and surgical and radiation therapy management strategies Review and debate the clinical utility and implications of novel genomic and pathologic diagnostic tools to subset breast cancer Assess the utility of algorithms and genomic tools to assess recurrence risk and predict benefit from adjuvant chemotherapy, hormonal therapy, and HER2-targeted therapy for individual patients Evaluate novel cytotoxic and biologic agents and their utility in neoadjuvant or adjuvant regimens Evaluate data from recent adjuvant chemotherapy clinical trials and use them to optimize and individualize treatment for patients with early-stage breast cancer Analyze the efficacy of adjuvant chemotherapy by breast cancer subtype Review the latest clinical data on adjuvant endocrine therapy, including up-front versus switching strategies and extended therapy with selective estrogen receptor modulators and aromatase inhibitors Apply key data on bisphosphonates from trials assessing outcomes on bone health and recurrence risk to the management of patients in defined clinical scenarios Discuss the recent clinical trial data that provide the underpinnings for state-of-the-art adjuvant and neoadjuvant systemic therapy for breast cancer Discuss the mechanisms of action of emerging chemotherapeutic, endocrine, and biologic agents; the rationale for and efficacy of novel combination regimens; and their potential place in therapy Guide patients to promising clinical trials...

The Eighth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy congress will address emerging data that underlie the optimal management of early-stage breast cancer. A significant emphasis on case discussion and available adjuvant and neoadjuvant treatment options will provide a forum to discuss and debate the controversies concerning and practical applicability of evolving clinical trial findings. Other topics pertaining to diagnosis, staging, breast cancer subtypes, risk assessment, toxicity management, and survivorship issues will also be addressed. The purpose of this congress is to provide an update on the latest advances in the management of early-stage breast cancer, addressing key areas of controversy.

The Eighth Annual Controversies in Breast Cancer: Adjuvant and Neoadjuvant Therapy congress will address emerging data that underlie the optimal management of early-stage breast cancer. A significant emphasis on case discussion and available adjuvant and neoadjuvant treatment options will provide a forum to discuss and debate the controversies concerning and practical applicability of evolving clinical trial findings. Other topics pertaining to diagnosis, staging, breast cancer subtypes, risk assessment, toxicity management, and survivorship issues will also be addressed. The purpose of this congress is to provide an update on the latest advances in the management of early-stage breast cancer, addressing key areas of controversy. Follow us on Twitter @ControBrCa www.twitter.com/ControBrCa

The Eighth International Congress on Gastrointestinal Malignancies is dedicated to an in-depth discussion of the best care options for the comprehensive management of patients with early- or advanced-stage gastrointestinal malignancies, including hepatocellular carcinoma and pancreatic, gastroesophageal, and colorectal cancers. This highly interactive meeting will include didactic lectures, debates, and case-based clinical presentations to provide a forum for discussion as well as context for the integration of recent advances in the clinical and surgical management of these malignancies. The optimal integration of biologic agents, such as antiangiogenic and EGFR-targeted agents, into current standard regimens across multiple lines of therapy in these diseases will be addressed and debated. The role of surgery and perioperative therapeutic regimens, including chemotherapy and multimodality therapies, in the treatment of patients with early-stage disease will also be discussed. Current controversies in the application of emerging clinical trial findings to daily practice will be debated by expert opinion leaders. Practical strategies to minimize treatment-related toxicities, such as neuropathy and skin toxicities, will also be reviewed. Furthermore, the genetics and molecular biology underlying prognostic and predictive assays, novel therapeutics on the horizon, and relevant high-priority clinical trials that are currently enrolling patients will be discussed. Target Audience This educational program is directed primarily toward medical oncologists, surgical oncologists, radiation oncologists, gastroenterologists, internal medicine and primary care physicians, basic researchers and investigators, practitioners, and fellows interested in liver, pancreatic, gastric, esophageal, and colorectal cancers. Nurses, physician assistants, and other individuals interested in the treatment of gastrointestinal malignancies and colorectal cancer are also welcome to attend. Learning Objectives At the conclusion of this congress, you should be able to: Explain the rationale and targets of therapy at the molecular level for novel agents in the treatment of gastroesophageal cancers Assess combination chemotherapy and chemoradiation therapy approaches in the neoadjuvant and perioperative settings for the treatment of gastric and esophageal cancer Analyze the efficacy and safety of chemotherapy regimens alone or combined with targeted agents in advanced gastroesophageal cancer Evaluate the impact of targeted therapies on the treatment of hepatocellular carcinoma Assess the potential impact of antiangiogenic and EGFR-targeted agents on the efficacy of conventional chemotherapy and outcome of patients with pancreatic cancer Discuss current concepts in the pathobiology and treatment of pancreatic cancer Interpret current issues and clinical data regarding surgical and chemotherapeutic treatment strategies for pancreatic cancer Assess biomarkers, such as KRAS, that are predictive of tumor response or toxicity profile for targeted and cytotoxic agents Utilize assay results to individualize treatment selection for patients with metastatic CRC Evaluate novel prognostic assays for their ability to assess recurrence risk in patients with localized CRC Assess recurrence risk factors for patients with stage II CRC to identify patients at increased risk of disease recurrence Evaluate standard of care adjuvant therapy options for individualized management of early-stage CRC Evaluate current standard of care therapy options for individualized management of metastatic CRC, including the use of antiangiogenic or EGFR-targeted agents in the first-line setting and beyond Assess differences in the efficacy and safety of fluoropyrimidine formulations as indicated by patient characteristics Evaluate the role of cytotoxic chemotherapies, targeted therapies, and surgery in the management of liver-only metastases in patients with CRC Identify specific adverse events associated with antiangiogenic or EGFR-targeted agents Review patient exposure to prior therapy with agents used in CRC and possible predisposition to treatment-related adverse events Evaluate treatment options, such as intermittent or continuous dosing, for patients experiencing acute and cumulative neuropathy due to platinum-containing therapy Identify advances in supportive care for treatment-associated toxicities in patients with CRC and other gastrointestinal malignancies Describe the rationale of investigational diagnostic and therapeutic strategies for gastrointestinal malignancies Assess the role of investigational treatment regimens and novel agents for gastrointestinal malignancies Identify appropriate patients for enrollment in clinical trials

The Eighth International Congress on Targeted Therapies in Cancer has been designed to provide participants with cutting-edge information on novel targeted anticancer therapies now being developed, highlighting the mechanisms of action of and the most current clinical data on those agents. The congress will detail the multiple signaling pathways that are disrupted in cancer as well as novel targeted approaches that specifically affect aberrant signaling in tumor cells, such as the mammalian target of rapamycin (mTOR) pathway; agents targeting the tumor microenvironment, including vascular disrupting agents and angiopoietin as well as inhibitors of vascular endothelial growth factor; agents targeting molecules involved in developmental pathways; and agents that harness the body’s own immune system to combat neoplastic disease. Clinical applications of novel imaging techniques will be discussed. The congress will also cover novel therapeutic and drug discovery platforms and will explore efforts to use combinatorial approaches to fine-tune the effectiveness of monoclonal antibodies. Furthermore, a preview of new agents on the horizon for specific tumor types will be presented. As the burgeoning field of targeted therapies continues to evolve, there is a clear need for physicians to be continuously updated on the most recent efficacy and safety data on these new classes of agents. The congress will use didactic learning and panel discussions to provide an educational program that allows physicians to keep abreast of these rapid developments.

The Eighth International Congress on the Future of Breast Cancer is an international educational and scientific meeting that focuses on the clinical implications of breast cancer genetic and phenotypic subtyping. New data and promising studies that provide information about how to optimally individualize breast cancer therapy will be the highlights of the congress. Key topics in breast cancer diagnosis and management will be discussed and controversial issues debated in multiple faculty panel discussions. Strategies for optimizing the use of endocrine therapy, conventional chemotherapy, and agents targeting HER2 or angiogenic pathways will be discussed. Evolving diagnostic approaches to identify the driving mutations or pathways in breast cancers will be thoroughly discussed, along with the therapies targeting those mutations. Controversial management issues in the surgical and radiotherapeutic management of breast cancer will be discussed and debated. The format will include didactic sessions from thought leaders, question-and-answer panel discussions, and ample time for participant interaction with faculty. This educational program is directed toward medical, surgical, and radiation oncologists practicing in the community or at academic institutions. Fellows, nurses, physician assistants, and pharmacists with an interest in the treatment of breast cancer are also invited to attend.

The Emerging Strategies in Women’s Cancers symposium has been designed to provide participants with cutting-edge information on the screening, diagnosis, and treatment of malignancies affecting women worldwide. This forum will focus on clinical and translational research in the areas of breast, ovarian, and cervical cancers, discussing not only standards of care and current guidelines, but also highlighting the most promising novel chemotherapeutics and targeted agents. Advances in diagnosis, prevention strategies, and risk assessment will also be addressed, particularly with regards to the role of tumor biology and genetics. For patients with breast cancer, increased cytotoxic and targeted therapeutic options require physicians to stay updated on the optimal incorporation of novel therapies into standard treatment regimens. The role of endocrine therapy in prevention and treatment of breast cancer is also expanding, further complicating the benefit-risk ratios for patients with hormone receptor-positive disease. Controversies in the combined modality approaches and chemotherapeutic management of ovarian carcinomas and issues revolving around prevention and treatment strategies for cervical cancer will also be discussed. The conference will use didactic lectures and case-based discussions to provide participants with ample opportunities to learn from and interact with key opinion leaders in the field.

Chairs: Bart Barlogie, MD, PhD and Elias J. Anaissie, MD

Institutional Insights in Multiple Myeloma, provides practical insight on how to apply the latest advances in diagnosis, prognosis, frontline therapy, treatments for relapsed/refractory disease, management of bone disease, and supportive care. Educational Objectives: At the completion of this program, the participants should be able to: 1. Identify the prognostic indicators and diagnostic approaches to multiple myeloma. 2. Discuss the latest advances in stem cell transplantation, treatments for bone disease, and supportive care management. 3. Describe the role and appropriate use of novel treatments for multiple myeloma throughout the disease progression.

Chair: Morton Coleman, MD Co-Chairs: John P. Leonard, MD, Ruben Niesvisky, MD, and Richard R. Furman, MD